Vernalis and Servier in two-year oncology collaboration
Shares in Vernalis rose more than 1% after it and Servier reinforced their partnership by entering into a new two-year oncology drug discovery collaboration on an undisclosed target.
FTSE AIM 100
3,724.78
17:14 03/05/24
n/a
n/a
FTSE AIM All-Share
771.53
17:14 03/05/24
n/a
n/a
Pharmaceuticals & Biotechnology
23,112.61
16:54 03/05/24
-0.42%
-97.18
Vernalis plc
6.17p
12:19 09/10/18
0.00%
0.00p
This extended the existing seven-year successful collaborations between the pair.
Vernalis would get a €2m upfront payment, fees, research milestones and a share in the downstream success of any products coming out of this new collaboration.
At 10:27 GMT, shares in AIM-quoted Vernalis were up 1.03% to 24.5p each.